AstraZeneca's Forxiga Approved in Japan - Analyst Blog

Comment

Shutterstock photo

AstraZeneca ( AZN ) announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). AstraZeneca and Japan-based Ono Pharmaceutical Co., Ltd. will co-promote Forxiga, a sodium glucose co-transporter-2 (SGLT2) inhibitor, in Japan.

We remind investors that the marketing application for Forxiga was submitted to MHLW by Bristol-Myers Squibb Company ( BMY ). However, AstraZeneca acquired full rights to Forxiga from Bristol-Myers in Feb 2014.

Forxiga is already approved in the U.S. (Jan 2014) and the EU (Nov 2012) for type II diabetes.

Our Take

We are pleased with the approval of Forxiga in Japan. According to the company, approximately 9.5 million people are suffering from type II diabetes in Japan. Generic competition has adversely impacted AstraZeneca's revenues over the past few quarters - this has put significant pressure on the company. In this context, the recent string of approvals for Forxiga and the subsequent up-take of the drug will give a much needed boost to the company's top line.

We note that Astellas Pharma, Inc. 's ( ALPMY ) Suglat, a SGLT2 inhibitor, which gained Japanese approval in January this year, has a head start over Forxiga. Meanwhile, Mitsubishi Tanabe Pharma's SGLT2 inhibitor, canagliflozin (U.S. trade name: Invokana) is currently under regulatory review in Japan.

AstraZeneca, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). A better-ranked stock in the biopharma sector is Alexion Pharmaceuticals, Inc. ( ALXN ). Alexion carries a Zacks Rank #1 (Strong Buy).



ASTELLAS PHARMA (ALPMY): Get Free Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
More Headlines for: ALPMY , ALXN , AZN , BMY


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com